A Case of Psoriasis Induced by Infliximab Treatment for Crohn's Disease

Abstract

Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has adverse events including infusion reactions, opportunistic infections, and the potential for the event such as reactivation of latent tuberculosis. Cutaneous adverse reactions of TNF-α agents include skin rash, urticaria, pruritus, lupus-like eruption, and injection site reactions. Most of all, psoriasis or psoriasiform dermatitis induced by infliximab treatment for Crohn's disease is rarely reported in Korea. We report a case of psoriasis induced by infliximab treatment for Crohn's disease with a review of world literature.

Psoriasis associated with anti‐tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature

“…13 There have been 23 cases reported in 12 publications that were not included in either of the above reviews. [16][17][18][19][20][21][22][23][24][25][26] Details on individual cases were not available for six patients in one series and were excluded from this analysis leaving a total of 58 cases. 27 The GETAID group described 62 cases, 48 of which occurred in patients with no prior history of psoriasis.…”

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up

“…One of the major concerns, despite its wide use, is potential development of ATI, which in turn may interfere with infliximab efficacy as mainly judged by observing the relapse of signs and symptoms of disease, and necessitates dose-escalation or potentially ending treatment [19]. After repeated dosing is performed, some patients have human antibodies to chimeric tumor necrosis factor-alpha antibodies [25,26]. Although ATI were evaluated in the current study, there were no significant findings.…”